Insomnia Labs and Next Steps: What to Test and When to Act

Why Insomnia Requires a Lab Workup

Insomnia is not just "trouble sleeping." In roughly 50% of chronic insomnia cases, an underlying medical condition contributes to or fully explains the sleep disruption [1]. Skipping labs means potentially treating a symptom while the root cause progresses unchecked.

Medical Conditions That Masquerade as Insomnia

Hypothyroidism, iron deficiency, uncontrolled diabetes, and hypercortisolism can all present with fragmented sleep as a primary complaint. A 2019 cross-sectional analysis in the Journal of Clinical Sleep Medicine found that patients with ferritin levels below 30 ng/mL were 2.7 times more likely to report chronic sleep-onset insomnia than those with levels above 75 ng/mL [2]. Thyroid dysfunction, even at subclinical levels (TSH between 4.5 and 10 mIU/L), has been linked to increased wake-after-sleep-onset (WASO) time in polysomnography studies [3].

When Labs Change the Treatment Plan

The practical value of a lab workup is directional. If ferritin comes back at 18 ng/mL, iron supplementation may resolve insomnia within 8-12 weeks without any sleep-specific medication. If fasting glucose is 118 mg/dL, the conversation shifts to metabolic health. Labs turn a vague complaint into an actionable clinical pathway.

The Recommended Lab Panel for Chronic Insomnia

The following panel covers the most common medical contributors to insomnia. Not every patient needs every test, but this baseline catches the conditions most frequently missed in primary care.

Thyroid Function: TSH and Free T4

Both hypothyroidism and hyperthyroidism disrupt sleep architecture. Hypothyroidism reduces slow-wave sleep. Hyperthyroidism increases nocturnal arousal frequency. The American Thyroid Association recommends TSH screening in any patient with unexplained fatigue or sleep disturbance [4]. Order TSH first. If TSH is abnormal (outside 0.4-4.0 mIU/L), add free T4 and free T3.

Iron Studies: Ferritin and CBC

Low ferritin is one of the most under-recognized causes of insomnia, particularly in premenopausal women and endurance athletes. Ferritin below 50 ng/mL has been associated with restless legs syndrome (RLS), a condition present in up to 15% of chronic insomnia patients [5]. A complete blood count (CBC) identifies anemia that ferritin alone may miss.

Metabolic Markers: Fasting Glucose and HbA1c

Poorly controlled blood sugar causes nocturnal hypoglycemia, nocturia, and autonomic arousals. The Sleep Heart Health Study (N=5,874) demonstrated that participants with HbA1c above 6.5% had 23% shorter total sleep time and 40% higher arousal index compared to normoglycemic controls [6]. Even prediabetic glucose levels (100-125 mg/dL) correlated with increased WASO.

Cortisol: When to Test and How

Do not order a random morning cortisol for insomnia. It is almost never useful. Late-night salivary cortisol or a 24-hour urinary free cortisol is appropriate only when clinical features suggest Cushing syndrome: unexplained weight gain, facial plethora, easy bruising, or proximal muscle weakness [7]. For patients with high perceived stress but no Cushingoid features, cortisol testing adds cost without changing management.

Additional Tests Based on Clinical Suspicion

Vitamin D (25-hydroxyvitamin D) may be worth checking. A meta-analysis of 9 studies (N=9,397) published in Nutrients found that serum 25(OH)D levels below 20 ng/mL were associated with a 50% increased risk of poor sleep quality [8]. Magnesium (RBC magnesium, not serum) can be informative in patients with muscle cramps or palpitations alongside insomnia. Testosterone, both total and free, should be measured in men over 40 with concurrent fatigue and low libido [9].

Diagnostic Tools Beyond Blood Work

Labs identify medical contributors. But insomnia diagnosis itself relies on validated instruments and, in select cases, objective sleep measurement.

Sleep Diaries and Validated Questionnaires

The Insomnia Severity Index (ISI) is a 7-item self-report measure that takes under 3 minutes to complete. Scores of 15 or above indicate moderate-to-severe clinical insomnia [10]. The Pittsburgh Sleep Quality Index (PSQI) captures broader sleep quality metrics. Both should be administered at baseline and repeated at 4-week intervals to track treatment response.

A two-week sleep diary is more diagnostically useful than any single night of data. It captures night-to-night variability, actual time in bed versus time asleep, and behavioral patterns (caffeine timing, screen use, irregular schedules) that questionnaires miss.

Polysomnography and Home Sleep Testing

A full in-lab polysomnography (PSG) is not indicated for uncomplicated insomnia. The American Academy of Sleep Medicine (AASM) practice parameters state that PSG should be reserved for suspected comorbid sleep disorders: obstructive sleep apnea (OSA), periodic limb movement disorder (PLMD), or narcolepsy [11]. Key red flags that warrant a sleep study include loud snoring, witnessed apneas, excessive daytime sleepiness (Epworth Sleepiness Scale score above 10), and BMI above 30.

Home sleep apnea testing (HSAT) is a reasonable first step for OSA screening. It is cheaper and more accessible than in-lab PSG. But HSAT underestimates the apnea-hypopnea index (AHI) by roughly 15-20%, so a negative HSAT in a high-pretest-probability patient should prompt in-lab confirmation [12].

Actigraphy

Wrist-worn actigraphy records rest-activity cycles over 7-14 days. It is most useful for circadian rhythm disorders (delayed sleep-wake phase disorder, irregular sleep-wake rhythm) rather than primary insomnia. The AASM recommends actigraphy as an adjunct, not a standalone diagnostic tool [13].

First-Line Treatment: CBT-I

Cognitive behavioral therapy for insomnia (CBT-I) is the recommended first-line treatment by every major guideline body, including the AASM, the American College of Physicians (ACP), and the European Sleep Research Society [14].

What CBT-I Actually Involves

CBT-I is a structured 4-to-8-session program with five core components: sleep restriction, stimulus control, cognitive restructuring, sleep hygiene education, and relaxation training. Sleep restriction is the most potent single component. It works by compressing time in bed to match actual sleep time, creating mild sleep deprivation that consolidates sleep architecture within 2-3 weeks.

A typical CBT-I protocol starts with a sleep diary showing 6.5 hours of actual sleep but 9 hours in bed. The clinician prescribes a "sleep window" of 11:30 PM to 6:00 AM. Once sleep efficiency (time asleep divided by time in bed) exceeds 85% for five consecutive nights, the window expands by 15-minute increments.

The Evidence Base

The ACP's 2016 clinical practice guideline, based on a systematic review of 44 studies, concluded that CBT-I produces clinically meaningful improvement in sleep onset latency (reduction of 19 minutes), WASO (reduction of 26 minutes), and sleep efficiency (increase of 9.9 percentage points) [15]. These effects persist at 12-month follow-up, unlike pharmacotherapy benefits, which typically revert within 2 weeks of discontinuation.

A 2021 randomized controlled trial in JAMA Internal Medicine (N=625) compared digital CBT-I (delivered via the Somryst platform, now Pear-004) to sleep hygiene education. Digital CBT-I reduced ISI scores by 7.6 points versus 4.4 points for education alone (P<0.001) [16].

Access to CBT-I

The biggest barrier to CBT-I is access. There are fewer than 1,000 board-certified behavioral sleep medicine specialists in the United States. Digital CBT-I programs (Somryst/Pear-004, Sleepio, CBT-I Coach from the VA) partially address this gap. The Society of Behavioral Sleep Medicine maintains a provider directory at behavioralsleep.org.

Second-Line Treatment: Pharmacotherapy

Medications are appropriate when CBT-I is unavailable, insufficient, or when the patient needs short-term relief while behavioral therapy takes effect.

Dual Orexin Receptor Antagonists (DORAs)

Suvorexant (Belsomra) and lemborexant (Dayvigo) block orexin signaling that maintains wakefulness. In the SUNRISE-2 trial (N=949), lemborexant 5 mg reduced sleep-onset latency by 11.6 minutes and increased total sleep time by 22.4 minutes versus placebo over 6 months, with no evidence of rebound insomnia upon discontinuation [17]. DORAs carry a lower abuse potential than benzodiazepine receptor agonists and do not suppress slow-wave sleep.

Low-Dose Doxepin

Doxepin at 3-6 mg (Silenor) selectively blocks histamine H1 receptors at these sub-antidepressant doses. It is FDA-approved for sleep-maintenance insomnia and is particularly useful in older adults because it does not impair balance or cognition at the 3 mg dose [18].

Benzodiazepine Receptor Agonists (Z-Drugs)

Zolpidem, zaleplon, and eszopiclone remain widely prescribed but carry real risks. The AASM's 2017 guidelines note that zolpidem is associated with complex sleep behaviors (sleep-driving, sleep-eating) and next-morning impairment, particularly in women, who metabolize the drug more slowly [19]. If prescribed, zolpidem should be used at the lowest effective dose (5 mg for women, 5-10 mg for men) for no more than 4 weeks.

Medications to Avoid

Over-the-counter diphenhydramine (Benadryl) and doxylamine (Unisom SleepTabs) develop tolerance within 3-7 days and carry anticholinergic burden that increases fall risk in older adults and has been associated with increased dementia risk in longitudinal cohort data [20]. Melatonin at typical OTC doses (3-10 mg) far exceeds physiologic replacement (0.3-0.5 mg) and has limited evidence for primary insomnia outside of circadian rhythm disorders.

When Insomnia Signals Something More Serious

Most insomnia is benign. Some is not. Recognize the red flags.

Insomnia Plus Unintentional Weight Changes

New-onset insomnia combined with weight gain, cold intolerance, and constipation points to hypothyroidism. Insomnia with weight loss, tremor, and heat intolerance suggests hyperthyroidism. Check TSH immediately.

Insomnia Plus Mood Symptoms

Insomnia is both a symptom and a risk factor for major depressive disorder. A meta-analysis of 21 longitudinal studies (N=34,402) found that insomnia doubled the risk of developing depression (OR 2.1, 95% CI 1.86-2.38) [21]. Screen with the PHQ-9. If the score is 10 or above, insomnia treatment alone is insufficient.

Insomnia in Perimenopause and Menopause

Up to 60% of perimenopausal and postmenopausal women report insomnia symptoms, driven by vasomotor symptoms (hot flashes, night sweats) and declining estradiol and progesterone levels [22]. In these patients, a hormone panel (estradiol, FSH, progesterone) provides diagnostic clarity. Hormone replacement therapy resolves vasomotor-associated insomnia in 70-80% of cases.

Building Your Personal Next-Steps Plan

A structured approach prevents both over-testing and under-treating.

Step 1: Quantify the Problem

Complete the ISI. Start a two-week sleep diary. This takes zero dollars and zero appointments.

Step 2: Get Baseline Labs

Request the core panel: TSH, free T4, ferritin, CBC, fasting glucose, HbA1c. Add vitamin D if you live above the 37th parallel or have limited sun exposure. Add total testosterone if you are male, over 40, and experiencing concurrent fatigue or low libido.

Step 3: Address Any Medical Findings

If labs reveal hypothyroidism, iron deficiency, or prediabetes, treat the underlying condition first. Insomnia may resolve without any sleep-specific intervention.

Step 4: Start CBT-I

Whether or not labs are abnormal, CBT-I should begin in parallel. Digital programs can be started the same week as lab work. Expect measurable improvement within 4-6 weeks.

Step 5: Reassess at 6-8 Weeks

Repeat the ISI. If scores remain above 14 despite CBT-I adherence and correction of any lab abnormalities, discuss pharmacotherapy with your clinician. DORAs or low-dose doxepin are reasonable second-line options.

The American Academy of Sleep Medicine recommends annual reassessment for patients on chronic hypnotic therapy, with a trial taper attempted at least once per year [19].